Arcutis aims to expand its market reach with new approvals. Management recently pleased the market with its sales guidance ...

Investing.com -- Arcutis Biotherapeutics Inc (NASDAQ:ARQT) stock rose 4.5% on Monday after the FDA accepted the company’s application to expand the use of its psoriasis treatment to younger children.

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in child ...

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical ...

ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three ...

These companies have exceptional dividend track records. AbbVie is moving on from its Humira patent losses, and its portfolio benefits from some exceptionally profitable products. Johnson & Johnson is ...

Icotronkinra results in significantly higher incidence of complete skin clearance at week 16 than placebo. HealthDay News — For adults and adolescents with moderate-to-severe plaque psoriasis, ...

ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remissionOver $500M cash ...

Antistreptococcal treatments could have therapeutic potential for psoriasis, but their efficacy is uncertain because of limited evidence, according to a recent literature review. Tonsillectomy, ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...